MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches

N Amodio, L Raimondi, G Juli, MA Stamato… - Journal of hematology & …, 2018 - Springer
The deeper understanding of non-coding RNAs has recently changed the dogma of
molecular biology assuming protein-coding genes as unique functional biological effectors …

[HTML][HTML] Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms

Y Chen, X Shao, X Zhao, Y Ji, X Liu, P Li… - Biomedicine & …, 2021 - Elsevier
The protein arginine methyltransferase 5 (PRMT5) as the major type II arginine
methyltransferase catalyzes the mono-and symmetric dimethylation of arginine residues in …

[HTML][HTML] Multiple myeloma: the (r) evolution of current therapy and a glance into the future

KC Anderson - Haematologica, 2020 - ncbi.nlm.nih.gov
Over the past 20 years, the regulatory approval of several novel agents to treat multiple
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …

Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity

N Amodio, MA Stamato, G Juli, E Morelli, M Fulciniti… - Leukemia, 2018 - nature.com
The biological role and therapeutic potential of long non-coding RNAs (lncRNAs) in multiple
myeloma (MM) are still to be investigated. Here, we studied the functional significance and …

Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma

E Taiana, V Favasuli, D Ronchetti, K Todoerti… - Leukemia, 2020 - nature.com
The biological role and therapeutic potential of long non-coding RNAs (lncRNAs) in multiple
myeloma (MM) are still open questions. Herein, we investigated the functional significance …

Multiple myeloma: challenges encountered and future options for better treatment

S Das, N Juliana, NAA Yazit, S Azmani… - International Journal of …, 2022 - mdpi.com
Multiple myeloma (MM) is a malignant hematological disease. The disease is characterized
by the clonal proliferation of malignant plasma cells in the bone marrow. MM accounts for …

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma

A Gullà, T Hideshima, G Bianchi, M Fulciniti… - Leukemia, 2018 - nature.com
Arginine methyltransferases critically regulate cellular homeostasis by modulating the
functional outcome of their substrates. The protein arginine methyltransferase 5 (PRMT5) is …

When oxidative stress meets epigenetics: implications in cancer development

Á García-Guede, O Vera, I Ibáñez-de-Caceres - Antioxidants, 2020 - mdpi.com
Cancer is one of the leading causes of death worldwide and it can affect any part of the
organism. It arises as a consequence of the genetic and epigenetic changes that lead to the …

Myeloma bone disease: a comprehensive review

SKR Mukkamalla, D Malipeddi - International journal of molecular …, 2021 - mdpi.com
Multiple myeloma (MM) is a neoplastic clonal proliferation of plasma cells in the bone
marrow microenvironment, characterized by overproduction of heavy-and light-chain …

Anti-tumor activity and epigenetic impact of the polyphenol oleacein in multiple myeloma

G Juli, M Oliverio, D Bellizzi, ME Gallo Cantafio… - Cancers, 2019 - mdpi.com
Olive oil contains different biologically active polyphenols, among which oleacein, the most
abundant secoiridoid, has recently emerged for its beneficial properties in various disease …